Views: 120 Author: Site Editor Publish Time: 2025-06-30 Origin: Site
CPHI Shanghai 2025 held grandly at the Shanghai New International Expo Centre from June 24th to 26th. As the largest and most influential pharmaceutical event in the Asia-Pacific region, this year's exhibition drew industry leaders from across the globe.
Biocom Pharma management team led a strong sales delegation to this prestigious gathering. Our booth attracted numerous visitors, facilitating deep exchanges and collaborative discussions with industry peers, experts, and partners, culminating in a highly fruitful conclusion.
Biocom's international sales team engaged with near hundred clients worldwide, holding in-depth discussions with customers from Europe, Japan & Korea, the Middle East, South America, and beyond. Promising collaboration intentions were established with dozens of these partners.
Our domestic sales team served a stream of clients from across China, providing detailed product introductions and answers to their inquiries. This active engagement supports clients competing in volume-based procurement and fosters new partnerships, garnering consistent positive feedback.
Key products showcased demonstrated significant market traction and competitiveness, including:
Desloratadine, Azilsartan Medoxomil Potassium, Vonoprazan Fumarate, Elagolix Sodium, Gefapixant Citrate, Resmetirom, Fezolinetant, etc.
Both our international and domestic sales managers provided clients with precise market and investment outlook analyses, uncovering valuable business opportunities and attracting numerous potential partners to our booth for inquiries.
Established in 2000, Biocom is a global high-end API supplier, MAH product operator, and high-quality healthcare solutions provider. Anchored in a global perspective, we have built an integrated pharmaceutical ecosystem encompassing: Innovative Drug R&D Platform, Generic Drug Development Platform, API Research Platform, Manufacturing Center (Shandong Loncom Pharmaceutical Co., Ltd), Bioequivalence (BE) Clinical Trial Platform, Post-Marketing Management System, MAH Licensing Platform. Adhering to the highest compliance standards and business integrity, and complying with ICH guidelines, our APIs and finished dosage forms (FDFs) are integrated into international supply chains. we will leverage AI-driven technologies and green manufacturing practices to deepen health collaboration under the Belt and Road Initiative, advancing China’s pharmaceutical innovations to benefit global communities and solidify our role as a core innovator in international healthcare.
As the exhibition concludes, Biocom extends heartfelt gratitude to all domestic and international clients, partners, and industry colleagues who visited our booth and offered their support and attention! Together, let's embrace the pulse of the pharmaceutical industry's evolution and set new milestones in the global story of China's pharmaceutical industry innovation.
